Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel

Papworth Hospital NHS Foundation Trust1 site in 1 countryJuly 2002

ConditionsIschemic Heart Disease

DrugsAspirin, Clopidogrel

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Ischemic Heart Disease
Sponsor: Papworth Hospital NHS Foundation Trust
Locations: 1
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.

Registry

clinicaltrials.gov

Start Date

July 2002

End Date

July 2004

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Papworth Hospital NHS Foundation Trust

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.

Exclusion Criteria

•Preoperative exclusion criteria:
•patients who are have not stopped aspirin 7 days prior to surgery
•patients on concomitant NSAIDS
•patients with a previous history platelet disorders, splenectomy or haematological disorders
•patients with aspirin induced asthma
•patients with any contraindications to aspirin (GI bleed)
•patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
•Women of childbearing potential
•Patients of less than 18 years
•If informed consent cannot be obtained